Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Magdalena Klanova"'
Autor:
Pavel Klener, Magdalena Klanova
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 6, p 2081 (2020)
Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of malignant transformation of mature lymphocytes during various stages of differentiation. The WHO classification of NHL recognizes more than 90 nosological units with p
Externí odkaz:
https://doaj.org/article/89254536612c40e490eb8ff1a184d996
Autor:
Michael Svaton, Zuzana Zemanova, Marek Trneny, Zuzana Nahacka, Magdalena Klanova, Jan Soukup, Mariana Pacheco-Blanco, Dana Prukova, Kristina Forsterova, Eva Fronkova, Jana Karolova, Karel Helman, Ladislav Andera, Pavel Klener, Karla Svobodova, Eva Pokorná, Ondrej Havranek, Petra Vockova, Adela Berkova, Diana Tuskova
Publikováno v:
Clinical Cancer Research. 25:4455-4465
Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over)expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of v
Autor:
Jie He, Tina Nielsen, Marek Trneny, Magdalena Klanova, Eugene Kim, Georg Lenz, Mikkel Z. Oestergaard, Umberto Vitolo, Joseph N. Paulson, Jing Tong, Alice Di Rocco, Laurie H. Sehn, Günter Fingerle-Rowson, Christopher R. Bolen
Publikováno v:
Haematologica
Diffuse large B-cell lymphoma represents a biologically and clinically heterogeneous diagnostic category with well-defined cell-of-origin subtypes. Using data from the GOYA study (NCT01287741), we characterized the mutational profile of diffuse large
Autor:
Magdalena Klanova, Ondrej Havranek, Karel Helman, Miroslav Strnad, Pavel Klener, Eva Pokorná, Dmitry Kazantsev, Alexandra Dolnikova, Radek Jorda, Diana Malarikova, Marek Trneny
Publikováno v:
Blood. 138:1203-1203
Introduction: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodkin lymphomas characterized by cyclin D1 overexpression, and other recurrent molecular-cytogenetic aberrations, including overexpression of BCL2, mutation or deletion
Autor:
Mikkel Z. Oestergaard, Umberto Vitolo, Laurie H. Sehn, Qingyuan Zhang, Tina Nielsen, Magdalena Klanova, Federico Mattiello, Gila Sellam, Francesco Zaja, Edith Szafer-Glusman, Douglas A. Stewart, Marek Trneny, Elizabeth Punnoose, Federica Cavallo, Guenter Fingerle-Rowson, Isabelle Bence-Bruckler, Jie Jin, Christopher R. Bolen, Maurizio Martelli
Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell lymphoma (DLBCL). Integrating biomarkers into the CNS–International Prognostic Index (CNS-IPI) risk model may improve identification of patients at high risk for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e38e8bd3bbc62eda95c58f85f2882fcd
http://hdl.handle.net/11573/1280165
http://hdl.handle.net/11573/1280165
Autor:
Magdalena Klanova, Jeffrey M. Venstrom, Marek Trněný, Mikkel Z. Oestergaard, Christian Klein, Umberto Vitolo, Andrea Knapp, Valentin Goede, Tina Nielsen, Robert Marcus, A. Cardona, Deniz Sahin, Wolfgang Hiddemann, Alexandra Bazeos, Laurie H. Sehn, Christopher R. Bolen, Harald Zeuner, Günter Fingerle-Rowson, Nathalie Spielewoy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(15)
Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with
Autor:
Robert Marcus, Roswitha Forstpointner, Mark Hertzberg, John Radford, Günter Fingerle-Rowson, Anna Maria Barbui, P.K. Cannell, Graham P. Collins, M. Wolbers, Kensei Tobinai, Michael Herold, Wolfgang Hiddemann, Jan Dürig, M. A. Canales Albendea, A. Burciu, Magdalena Klanova, Tina Nielsen
Publikováno v:
Hematological Oncology. 35:117-119
Autor:
Jan Dürig, Marcel Wolbers, Miguel Canales, Roswitha Forstpointner, Tina Nielsen, Wolfgang Hiddemann, John Radford, John F. Seymour, Anna Maria Barbui, Günter Fingerle-Rowson, Graham P. Collins, Kensei Tobinai, Michael Herold, Magdalena Klanova, Robert Marcus, Mark Hertzberg, Paul Cannell, Alis Burciu, Judith Trotman
Publikováno v:
Hiddemann, W, Barbui, A M, Canales, M A, Cannell, P K, Collins, G P, Dürig, J, Forstpointner, R, Herold, M, Hertzberg, M, Klanova, M, Radford, J, Seymour, J F, Tobinai, K, Trotman, J, Burciu, A, Fingerle-rowson, G, Wolbers, M, Nielsen, T & Marcus, R E 2018, ' Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety ', Journal of Clinical Oncology, vol. 36, no. 23, pp. 2395-2404 . https://doi.org/10.1200/JCO.2017.76.8960
Purpose The GALLIUM study ( ClinicalTrials.gov identifier: NCT01332968) showed that obinutuzumab (GA101; G) significantly prolonged progression-free survival (PFS) in previously untreated patients with follicular lymphoma relative to rituximab (R) wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bccfbfe5d992da37c96025fecf31905
https://research.manchester.ac.uk/en/publications/cbc3c501-f603-4670-ba59-80f34e7e1c8c
https://research.manchester.ac.uk/en/publications/cbc3c501-f603-4670-ba59-80f34e7e1c8c
Autor:
Jan Soukup, Ladislav Andera, Jana Karolova, Diana Tuskova, Eva Pokorná, Dana Prukova, Petra Vockova, Marek Trněný, Zuzana Zemanova, Magdalena Klanova, Michael Svaton, Pavel Klener, Ondrej Havranek, Zuzana Nahacka, Kristina Forsterova, Eva Fronkova
Publikováno v:
Blood. 132:42-42
Introduction Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over)expression of BCL2 and good sensitivity to a small molecule BCL2 inhibitor venetoclax. In the present study we analyzed molecular
Autor:
Andrea Knapp, Laurie H. Sehn, Marek Trněný, Christopher R. Bolen, Valentin Goede, Tina Nielsen, Denis Sahin, Nathalie Danesi, Jeffrey M. Venstrom, Harald Zeuner, Susan Robson, Günter Fingerle-Rowson, Magdalena Klanova, Wolfgang Hiddemann, Alexandra Bazeos, Robert Marcus, Mikkel Z. Oestergaard, Umberto Vitolo
Publikováno v:
Blood. 130:727-727
Introduction: Natural killer (NK) cells are key elements of the innate immune system. Obinutuzumab (GA101; G) is an anti-CD20 monoclonal antibody with enhanced direct cell death activity and antibody-dependent cellular cytotoxicity (ADCC) vs rituxima